Partnerships
Aspivix carevix Cervical Stabilizer Added to Afaxys GPO for US Public Health Providers
By News Desk ·
Key takeaways
- Aspivix and Afaxys announced an agreement making carevix available to all Afaxys members across the United States.
- carevix is an FDA-cleared suction-based cervical stabilizer associated with up to 73% less pain and 83% less bleeding during IUD insertion compared with the tenaculum.
- A post-marketing study evaluated 1,123 IUD placements across 19 centers, with 94% of participants satisfied with their experience.
Aspivix and Afaxys announced an agreement on October 19, 2026, making carevix, an FDA-cleared suction-based cervical stabilizer, available to all Afaxys members across the United States. PR Newswire published the announcement. The agreement gives community and public health providers streamlined access to the device for cervical stabilization during intrauterine device placement and other transcervical procedures.
How the Afaxys GPO Agreement Works
carevix is described as the world's first clinically proven suction-based cervical stabilizer, designed as a modern alternative to the century-old tenaculum, a sharp-toothed forceps still widely used in gynecology. Clinical studies have demonstrated that the suction technology is associated with an up to 73% reduction in pain and an 83% reduction in bleeding during IUD insertion compared with the traditional tenaculum. Through the Afaxys GPO, a group purchasing organization, the agreement creates a new pathway for adoption among members including community and public health providers. Afaxys members can request a complimentary carevix sample and obtain product or ordering support by contacting the company.
The agreement aligns with the patient-centered direction of the American College of Obstetricians and Gynecologists' 2025 Clinical Consensus on pain management for in-office uterine and cervical procedures. ACOG emphasizes counseling patients about potential pain, shared decision-making, and offering individualized pain-management options. "Joining forces with the Afaxys GPO is an important milestone in our mission to make gentler gynecological care available to more women across the USA," said Mathieu Horras, CEO of Aspivix. "Together, we are on a mission to accelerate access to an innovation designed to improve the IUD experience and give more patients the care they deserve."
What the carevix Clinical Data Show
A prospective post-marketing study evaluated 1,123 IUD placements across 19 centers, including sites in the United States. Overall, 94% of participants were satisfied with their experience, up to 73% reported less pain than expected, and 82% of healthcare professionals were satisfied with carevix, citing ease of use, visibility, and low patient discomfort. According to akta.pro company records, Aspivix published multicenter post-marketing study results in the International Journal of Gynecology & Obstetrics in February 2026 covering 1,123 IUD procedures across 19 sites in 9 countries. The same records show Aspivix launched carevix commercially in the United States in Southern California and New York in October 2025 following FDA clearance.
Aspivix's Path to the Afaxys Agreement
Aspivix closed its second crowdfunding campaign on Capital Cell in September 2026, raising €836,285 against a €675,545 target, a 123.8% oversubscription, BioAlps reported. The company's carevix cervical stabilizer is marketed in 19 countries and has generated commercial revenue, according to BioAlps. In June 2026, Aspivix launched a new crowdfunding campaign on Capital Cell following its 2025 campaign that raised €1.9 million from over 300 investors, BioAlps reported. The new round totals CHF 2-4 million, with investments starting at €800, to accelerate commercial development and US and European growth.
carevix has received FDA clearance, CE-Mark, MHRA, and ANVISA approval, and is available for commercialization in the U.S., Switzerland, UK, and Benelux. Additional information is available at Aspivix's website.